Alentis and PinotBio partner to develop claudin-1 oncology ADCs

Alentis Therapeutics and PinotBio have entered into a research collaboration and licensing agreement to develop claudin-1-targeting antibody-drug conjugates (ADCs) for oncology indications. The post Alentis and PinotBio partner to develop claudin-1 oncology ADCs appeared first on Hospital Management.